Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Santen Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Santen Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Santen Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Santen Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Santen Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate Santen Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Santen Pharmaceutical Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Santen Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Santen Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Santen Pharmaceutical Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Santen Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Santen Pharmaceutical Co., Ltd. Snapshot 6
Santen Pharmaceutical Co., Ltd. Overview 6
Key Information 6
Key Facts 6
Santen Pharmaceutical Co., Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Santen Pharmaceutical Co., Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Santen Pharmaceutical Co., Ltd. - Pipeline Products Glance 15
Santen Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Filing rejected/Withdrawn Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
Santen Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Santen Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Santen Pharmaceutical Co., Ltd. - Drug Profiles 21
(tafluprost + timolol maleate) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
cyclosporine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
diquafosol tetrasodium 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
tafluprost 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
levofloxacin 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
sirolimus 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
betamethasone 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
DE-117 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
latanoprost 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
lomerizine 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
DE-120 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
dexamethasone dipropionate 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
SA-14867 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SA-981 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
TRC-105 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Santen Pharmaceutical Co., Ltd. - Pipeline Analysis 43
Santen Pharmaceutical Co., Ltd. - Pipeline Products by Target 43
Santen Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 45
Santen Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 46
Santen Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 47
Santen Pharmaceutical Co., Ltd. - Recent Pipeline Updates 49
Santen Pharmaceutical Co., Ltd. - Dormant Projects 54
Santen Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 55
Discontinued Pipeline Product Profiles 55
DE-098 55
DE-104 55
DE-105 55
evodenoson 55
gefarnate 55
olmesartan 56
ONO-6126 56
rivoglitazone 56
Santen Pharmaceutical Co., Ltd. - Company Statement 57
Santen Pharmaceutical Co., Ltd. - Locations And Subsidiaries 58
Head Office 58
Other Locations & Subsidiaries 58
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62

List of Tables
Santen Pharmaceutical Co., Ltd., Key Information 6
Santen Pharmaceutical Co., Ltd., Key Facts 6
Santen Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014 9
Santen Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 10
Santen Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 11
Santen Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014 12
Santen Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014 13
Santen Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 14
Santen Pharmaceutical Co., Ltd. - Pre-Registration, 2014 15
Santen Pharmaceutical Co., Ltd. - Filing rejected/Withdrawn, 2014 16
Santen Pharmaceutical Co., Ltd. - Phase III, 2014 17
Santen Pharmaceutical Co., Ltd. - Phase II, 2014 18
Santen Pharmaceutical Co., Ltd. - Phase I, 2014 19
Santen Pharmaceutical Co., Ltd. - Preclinical, 2014 20
Santen Pharmaceutical Co., Ltd. - Pipeline by Target, 2014 44
Santen Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014 45
Santen Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014 46
Santen Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 48
Santen Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014 49
Santen Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014 54
Santen Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2014 55
Santen Pharmaceutical Co., Ltd., Other Locations 58
Santen Pharmaceutical Co., Ltd., Subsidiaries 59